Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control

International Journal of Antimicrobial Agents

Volumn 28, Issue 5, 2006, Pages 379-384

  Gould, I M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Costs; Hospital acquired MRSA

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CHLORHEXIDINE; GLYCOPEPTIDE;

ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HOSPITAL COST; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONHUMAN; PATIENT CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; COST OF ILLNESS; CROSS INFECTION; HOSPITAL COSTS; HUMANS; INFECTION CONTROL; METHICILLIN; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33750332137     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.09.001     Document Type: Short Survey

References (62)

1. Lacey R.W. Multi-resistant Staphylococcus aureus-a suitable case for inactivity?. J Hosp Infect 9 (1987) 103-105
2. European Antimicrobial Resistance Surveillance System annual report 2005. http://www.rivm.nl/earss/result/Monitoring_reports/ (accessed 6 September 2006).
3. Diekema D.J., BootsMiller B.J., Vaughn T.E., et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 38 (2004) 78-85
4. Moellering Jr. R.C. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 144 (2006) 368-370
5. Hageman J.C., Uyeki T.M., Francis J.S., et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 6 (2006) 894-899
6. Cosgrove S.E., Sakoulas G., Perencevich E.N., et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36 (2003) 53-59
7. Whitby M., McLaws M.L., and Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 175 (2001) 264-267
8. Shorr A.F., Combes A., Kollef M.H., et al. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 34 (2006) 700-706
9. Gould I.M. The clinical significance of methicillin-resistant Staphylococcus aureus. J Hosp Infect 61 (2005) 277-282
10. Steinberg J.P., Clark C.C., and Hackman B.O. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 23 (1996) 255-259
11. Department of Health. The third year of regional and national analyses of the Department of Health's mandatory MRSA surveillance scheme in England: April 2001-March 2004. CDR Wkly 2004;14:1-6.
12. Pollard T.C., Newman J.E., Barlow N.J., et al. Deep wound infection after proximal femoral fracture: consequences and costs. J Hosp Infect 63 (2006) 133-139
13. Rello J., Sole-Violan J., Sa-Borges M., et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 33 (2005) 1983-1987
14. MacKenzie F.M., Greig P., Morrison D., et al. Identification and characterization of teicoplanin-intermediate Staphylococcus aureus blood culture isolates in NE Scotland. J Antimicrob Chemother 50 (2002) 689-697
15. Reed S.D., Friedman J.Y., Engemann J.J., et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 26 (2005) 175-183
16. Abramson M.A., and Sexton D.J. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs?. Infect Control Hosp Epidemiol 20 (1999) 408-411
17. Chaix C., Durand-Zaleski I., Alberti C., et al. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 282 (1999) 1745-1751
18. Cosgrove S.E., Qi Y., Kaye K.S., et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26 (2005) 166-174
19. Rubin R.J., Harrington C.A., Poon A., et al. The economic impact of Staphylococcus aureus infection in New York city hospitals. Emerg Infect Dis 5 (1999) 9-17
20. Engemann J.J., Carmeli Y., Cosgrove S.E., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36 (2003) 592-598
21. Herr C.E.W., Heckrodt T.H., Hofmann F.A., et al. Additional costs for preventing the spread of methicillin-resistant Staphylococcus aureus and a strategy for reducing these costs on a surgical ward. Infect Control Hosp Epidemiol 24 (2003) 673-678
22. Wernitz M.H., Keck S., Swidsinski S., et al. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin Microbiol Infect 11 (2005) 466-471
23. McGarry S.A., Engemann J.J., Schmader K., et al. Surgical-site infection due to Staphylococcus aureus among elderly patients: mortality, duration of hospitalization, and cost. Infect Control Hosp Epidemiol 25 (2004) 461-467
24. Papia G., Louie M., Tralla A., et al. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective?. Infect Control Hosp Epidemiol 20 (1999) 473-477
25. Perencevich E.N., Fisman D.N., Lipsitch M., Harris A.D., Morris J.G., and Smith D.L. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis 38 (2004) 1108-1115
26. Lucet J.C., Chevret S., Zaleski I.D., et al. Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study. Arch Intern Med 163 (2003) 181-188
27. Haglind B.E. Cost-savings achieved by eradication of epidemic methicillin-resistant Staphylococcus aureus (EMRSA)-16 from a large teaching hospital. Eur J Clin Microbiol Infect Dis 23 (2004) 688-695
28. Karchmer T.B., Durbin L.J., Simonton B.M., et al. Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J Hosp Infect 51 (2002) 126-132
29. Vriens M., Blok H., Fluit A., et al. Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch University Medical Center: a 10 year survey. Eur J Clin Microbiol Infect Dis 21 (2002) 782-786
30. Lally R.T., Lanz E., and Schrock C.G. Rapid control of an outbreak of Staphylococcus aureus on a neonatal intensive care department using standard infection control practices and nasal mupirocin. Am J Infect Control 32 (2004) 44-47
31. Rumbak M.J., and Cancio M.R. Significant reduction in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia associated with the institution of a prevention protocol. Crit Care Med 23 (1995) 1200-1203
32. Cosseron-Zerbib M., Roque Afonso A.M., Naas T., et al. A control programme for MRSA (methicillin-resistant Staphylococcus aureus) containment in a paediatric intensive care unit: evaluation and impact on infections caused by other micro-organisms. J Hosp Infect 40 (1998) 225-235
33. Khoury J., Jones M., Grim A., et al. Eradication of methicillin-resistant Staphylococcus aureus from a neonatal intensive care unit by active surveillance and aggressive infection control measures. Infect Control Hosp Epidemiol 26 (2005) 616-621
34. Muller A., Talon D., Potier A., et al. Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units. Crit Care 9 (2005) 257-258
35. Pan A., Carnevale G., Catenazzi P., et al. Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA 'search and isolate' strategy in a hospital in Italy with hyperendemic MRSA. Infect Control Hosp Epidemiol 26 (2005) 127-133
36. Jernigan J.A., Titus M.G., Groschel D.H., et al. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol 143 (1996) 496-504
37. Blumberg L.H., and Klugman K.P. Control of methicillin-resistant Staphylococcus aureus bacteraemia in high-risk areas. Eur J Clin Microbiol Infect Dis 13 (1994) 82-85
38. Valls V., Gómez-Herruz P., González-Palacios R., et al. Long-term efficacy of a program to control methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 13 (1994) 90-95
39. Plowman R., Graves N., Griffin M.A.S., et al. The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. J Hosp Infect 47 (2001) 198-209
40. Gammon J. The psychological consequences of source isolation: a review of the literature. J Clin Nurs 8 (1999) 13-21
41. Burnie J., Matthews R., Jiman-Fatami A., et al. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin Infect Dis 31 (2000) 684-689
42. Ritchie K, Iqbal K, Macpherson K, Riches E, Stout A. The provision of alcohol-based products to improve compliance with hand hygiene. Health Technology Assessment Report 7. NHS Quality Improvement Scotland; 2005.
43. LeDell K., Muto C.A., Jarvis W.R., et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 24 (2003) 639-641
44. Ritchie K, Bradbury I, Eastgate J, et al. Consultation Report on Health Technology. Clinical and cost effectiveness of screening for MRSA. NHS Quality Improvement Scotland; 2006.
45. Chaix C., Durand-Zaleski I., Alberti C., et al. A model to compute the medical cost of patients in intensive care. Pharmacoeconomics 15 (1999) 573-582
46. Gould IM, editor. Treatment of MRSA. In: MRSA in practice. London, UK: Royal Society of Medicine; 2006 (in press).
47. Nathwani D. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?. J Antimicrob Chemother 51 Suppl 2 (2003) ii37-ii44
48. Wilcox M.H. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother 6 (2005) 2315-2326
49. Laupland K.B., Lee H., Gregson D.B., et al. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect 63 (2006) 124-132
50. Indiana University Media Relations. Employee-led effort dramatically reduces rates of hospital super bug. Indiana University study sees reduction in methicillin-resistant Staphylococcus aureus. http://newsinfo.iu.edu/news/page/normal/2695.html (accessed 5 September 2006).
51. Rello J., Ochagavia A., Sabanes E., et al. Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Respir Crit Care Med 16 (2000) 1027-1030
52. Dimick J.B., Pelz R.K., Consunji R., et al. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg 136 (2001) 229-234
53. Rojas E, Liu LZ. Annual cost for the treatment of patients hospitalized with methicillin-resistant Staphylococcus aureus in the United States. In: 10th Annual International Meeting of the Society for Pharmacoeconomics and Outcomes Research; 2005 May 15-18; Washington, DC. Value Health 2005; 8:308 (abstract no. PINI3).
54. Noskin G.A., Rubin R.J., Schentag J.J., et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 165 (2005) 1756-1761
55. Cox R.A., Conquest C., Mallaghan C., et al. A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16). J Hosp Infect 29 (1995) 87-106
56. Smith R.D., Yago M., Millar M., et al. Assessing the macroeconomic impact of a healthcare problem: the application of computable general equilibrium analysis to antimicrobial resistance. J Health Econ 24 (2005) 1055-1075
57. Gould I.M., MacKenzie F.M., MacLennan G., et al. Patient decontamination to control MRSA in an intensive care unit. Clin Microbiol Infect 12 Suppl 4 (2006) 51 (Poster 1336)
58. Lopez-Lozano J.M., Beyaert A., MacKenzie F.M., et al. Effect of an intervention programme on the MRSA outbreak in Aberdeen Royal Infirmary. Clin Microbiol Infect 10 Suppl 3 (2004) 131
59. National Audit Office. The management and control of hospital acquired infection in acute NHS Trusts in England. Report by the Comptroller and Auditor General. HC 230 Session 1999/2000. London, UK: National Audit Office; 2000.
60. Cooper B.S., Medley G.F., Stone S.P., et al. Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proc Natl Acad Sci USA 101 (2004) 10223-10228
61. Bootsma M.C.J., Diekmann O., and Bonten M.J.M. Controlling methicillin-resistant Staphylococcus aureus: quantifying the effect of interventions and rapid diagnostic testing. Proc Natl Acad Sci USA 103 (2006) 5620-5625
62. The greatest story never told? ICPs must raise voice on infection prevention. Former health secretary key notes, APIC in Tampa. Hosp Infect Control 2006;33:73-84.